2013年美国冷冻卵母细胞与新鲜卵母细胞辅助生殖技术周期的比较
基于美国国家辅助生殖技术监测系统的回顾性队列研究,比较2013年启动的新鲜胚胎周期中使用新鲜与冷冻自体及供体卵母细胞者的特征、预测因素及周期、移植和妊娠结局。自体和供体新鲜与冷冻卵母细胞周期在取消、种植、妊娠、流产或活产率上无差异证据,但供体冷冻卵母细胞周期在每周期和每妊娠结局上有差异,每移植结局无差异。
要点
- 自体和供体新鲜与冷冻卵母细胞周期在取消、种植、妊娠、流产或活产率上无差异证据。
- 供体冷冻卵母细胞周期取消风险降低(aRR 0.74,95%CI 0.57-0.96),妊娠可能性降低(aRR 0.88,95%CI 0.81-0.95),活产可能性降低(aRR 0.87,95%CI 0.80-0.95)。
- 供体冷冻卵母细胞周期中,移植一枚胚胎者流产风险降低(aRR 0.75,95%CI 0.58-0.97)且活产率升高(aRR 1.05,95%CI 1.01-1.09),移植两枚或以上者流产风险升高(aRR 1.28,95%CI 1.07-1.54)且活产率降低(aRR 0.95,95%CI 0.92-0.99)。
核心结论
- 自体和供体新鲜与冷冻卵母细胞周期在辅助生殖技术结局上无差异证据。
- 供体冷冻与新鲜卵母细胞周期在每周期和每妊娠结局上有差异证据,但每移植结局无差异。
研究设计与样本
- 美国国家辅助生殖技术监测系统的回顾性队列研究,纳入2013年启动的使用新鲜和冷冻自体及供体卵母细胞创建胚胎的新鲜胚胎周期。
主要发现
- 自体和供体新鲜与冷冻卵母细胞周期在取消、种植、妊娠、流产或活产率上无差异证据。
- 供体冷冻卵母细胞周期取消风险降低(aRR 0.74,95%CI 0.57-0.96),妊娠可能性降低(aRR 0.88,95%CI 0.81-0.95),活产可能性降低(aRR 0.87,95%CI 0.80-0.95)。
- 供体冷冻卵母细胞周期中,仅限移植周期时种植、妊娠或活产率无差异证据。
- 供体冷冻卵母细胞周期中,移植一枚胚胎者流产风险降低(aRR 0.75,95%CI 0.58-0.97)且活产率升高(aRR 1.05,95%CI 1.01-1.09),移植两枚或以上者流产风险升高(aRR 1.28,95%CI 1.07-1.54)且活产率降低(aRR 0.95,95%CI 0.92-0.99)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare characteristics, explore predictors, and compare assisted reproductive technology (ART) cycle, transfer, and pregnancy outcomes of autologous and donor cryopreserved oocyte cycles with fresh oocyte cycles. DESIGN: Retrospective cohort study from the National ART Surveillance System. SETTING: Fertility treatment centers. PATIENT(S): Fresh embryo cycles initiated in 2013 utilizing embryos created with fresh and cryopreserved, autologous and donor oocytes. INTERVENTION(S): Cryopreservation of oocytes versus fresh. MAIN OUTCOMES MEASURE(S): Cancellation, implantation, pregnancy, miscarriage, and live birth rates per cycle, transfer, and/or pregnancy. RESULT(S): There was no evidence of differences in cancellation, implantation, pregnancy, miscarriage, or live birth rates between autologous fresh and cryopreserved oocyte cycles. Donor cryopreserved oocyte cycles had a decreased risk of cancellation before transfer (adjusted risk ratio [aRR] 0.74, 95% confidence interval [CI] 0.57-0.96) as well as decreased likelihood of pregnancy (aRR 0.88, 95% CI 0.81-0.95) and live birth (aRR 0.87, 95% CI 0.80-0.95); however, there was no evidence of differences in implantation, pregnancy, or live birth rates when cycles were restricted to those proceeding to transfer. Donor cryopreserved oocyte cycles proceeding to pregnancy had a decreased risk of miscarriage (aRR 0.75, 95% CI 0.58-0.97) and higher live birth rate (aRR 1.05, 95% CI 1.01-1.09) with the transfer of one embryo, but higher miscarriage rate (aRR 1.28, 95% CI 1.07-1.54) and lower live birth rate (aRR 0.95, 95% CI 0.92-0.99) with the transfer of two or more. CONCLUSION(S): There was no evidence of differences in ART outcomes between autologous fresh and cryopreserved oocyte cycles. There was evidence of differences in per-cycle and per-pregnancy outcomes between donor cryopreserved and fresh oocyte cycles, but not in per-transfer outcomes.
引用
- Crawford S, Boulet SL, Kawwass JF, et al. Cryopreserved oocyte versus fresh oocyte assisted reproductive technology cycles, United States, 2013. Fertil Steril. 2016. PMID: 27842997. doi:10.1016/j.fertnstert.2016.10.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。